Bank of America
ESPR

Bank of America’s Esperion Therapeutics ESPR Stock Holding History

Bank of America’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-16,700
Closed -$84K – 8394
2021
Q4 		$84K Sell
16,700
-7,600
-31% -$60.9K ﹤0.01% 6964
2021
Q3 		$293K Buy
+24,300
New +$354K ﹤0.01% 6024
2015
Q3 		– Sell
-30,000
Closed -$2.45M – 7265
2015
Q2 		$2.45M Buy
+30,000
New +$2.94M ﹤0.01% 3269

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's ESPR Position: Q1 2026 in Review

Bank of America reduced its Esperion Therapeutics (ESPR) stake by 64% in Q1 2026, selling an estimated $1.42M and leaving 249,395 shares worth $683K. The position accounts for ﹤0.01% of the portfolio, ranked #4725.

Bank of America first reported a position in ESPR in Q3 2013 and has held it in 51 quarters since. The position peaked at $14.3M in Q2 2015. 206 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Bank of America held 249,395 shares of Esperion Therapeutics worth $683K as of Q1 2026.
  • Bank of America sold 447,395 Esperion Therapeutics shares in Q1 2026, an estimated $1.42M.
  • Esperion Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4725 holding.
  • Bank of America first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 51 quarters since.
  • Bank of America's Esperion Therapeutics position peaked at $14.3M in Q2 2015.
  • 206 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.